Eli Lilly has announced that it plans to submit Orforglipron to the FDA for regulatory review this year (2025) for weight loss, and in 2026 for type 2 diabetes
To strengthen the studys validity, it would be beneficial to assess factors such as CPT I, the key enzyme controlling the mitochondrial transportation of long-chain fatty acids, OCTN2, the carnitine transporter gene, AMPK, and malonyl-CoA
Data availability All data supporting the findings of this study are available within the article and its supplementary materials
These can include pain or redness at the injection site, mild diarrhea, and a feeling of swelling over the entire body [1]
Subjective results (sleep, energy, recovery) begin within 2-3 weeks
Krul-Poel YH, Agca R, Lips P, van Wijland H, Stam F, Simsek S